PATENT CLAIM ANALYSIS

Application Number: 16159674
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "506000"]

Abstract:
Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators.

Claim (Index 8):
The method according to  claim 4 , wherein said joint is the temporomandibular joint.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.19565
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16129569', '14507730', '12790533', '10356649', '14661656']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7229741161327995
- 35 USC 102 Novelty (BERT): 0.485303940336472
- Combined Prediction Score: 0.6992070985531668
- Mean Citation Score: 147.337094
- Max Citation Score: 155.71175
- Similarity Product: 102.90837296256424

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test